Midi Estriol+ Face Cream: a review of the actual product records

The main listing calls the product Estriol+ Face Cream and advertises a $149 price for a 90-day supply of 90 mL. The express listing describes that amount as three pump dispensers of 30 mL each. Both concern a facial cream, rather than a vaginal estrogen product or a systemic menopause medicine. Current listing and express listing.

That physical amount is useful documentation, but the stated supply period is not a personal treatment duration. Our commercial comparison preserves those sale units without assuming that equal calendar periods represent equal exposures, results or clinical needs across providers.

The express FAQ's advertised active list gives estriol 0.3%, DMAE 0.3% and hyaluronic acid 0.5%. It also names ethoxy diglycol and an emollient base containing ingredients such as water, isopropyl myristate, propylene glycol and dimethicone. That is a published formula description, not independent confirmation of a supplied batch. Express ingredient record.

The linked monograph agrees on estriol and hyaluronic acid but specifies DMAE at 3%. We cannot resolve that difference by choosing the larger or smaller number, treating it as an established typo or borrowing another pharmacy's formula. The appropriate supplied concentration remains a question for Midi and the dispensing record. Linked monograph.

Midi's express copy says topical estriol does not increase circulating hormone levels and frames it as safe for most women. We report this as company wording, not a universal safety conclusion. The reviewed product pages do not supply enough product-specific pharmacokinetic evidence to establish absent absorption in all users. Express claims.

FDA says there are no approved estriol drugs and that it lacks evidence establishing estriol as a safer estrogen. The hormone-identity article explains why facial use and a gentler-sounding description do not remove hormonal activity. A qualified prescriber needs to assess the actual preparation and relevant history. FDA context.

The express record links research concerning estrogen and skin, including the 1996 study of estradiol and estriol preparations. Its abstract concerns 59 preclimacteric women and skin outcomes over six months. The abstract does not establish that Midi's present cream, with its other ingredients and unresolved DMAE specification, was the tested formulation. Primary abstract.

The hydration-versus-firmness guide distinguishes the study's different outcome categories. Midi's testimonials likewise describe selected experiences rather than a controlled evaluation of everyone prescribed the current product. They cannot establish a typical response rate, a diagnosis or hormone-related safety for another person.

The main page says the process can begin without a visit: health questions and payment information are followed by clinician review, then charging and shipping if approved. It says approval usually occurs within 24 hours. These are the provider's process and time claims; we did not test them. Main-page process.

The express FAQ instead tells readers to book a clinician visit to discuss suitability. That leaves the applicable access route worth confirming. Neither the no-visit headline nor an advertised turnaround should be treated as guaranteed approval or proof that the same evaluation is available to every person in every circumstance.

The $149 product offer is tied to its stated quantity and supply period. Our reviewed record does not verify an individual final charge, shipping adjustment, renewal arrangement or any separate consultation charge that might apply to the actual pathway. It would be misleading to convert that product price into a guaranteed complete cost of care. Product offer.

The Time Out review has a different kind of term-based offer. Comparing prices remains possible as a reading exercise, but an honest comparison retains what the charge is for and what has not been established. It does not invent a uniform monthly cost or imply equivalent treatment.

A useful clarification request identifies the exact product, the differing DMAE concentrations and the relevant access-page wording. The actual prescription and dispensing documents can then be distinguished from the public advertising. FDA explains that compounded preparations do not receive its premarket safety, effectiveness and quality verification. A detailed ingredient list does not change that status. FDA compounding explanation.

Our product-record guide keeps those boundaries together. The Alloy serum review presents a different evidence mismatch: cream study claims on a serum page. Neither review supplies an application routine or substitutes for professional assessment of an estrogen-containing preparation.